Skip to main content
SpringerLink
Log in

Polymorphism of A118G in μ-opioid receptor gene is associated with risk of esophageal squamous cell carcinoma in a Chinese population

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Previous studies have indicated a direct effect of μ-opioid receptors on tumor progression or recurrence. An A118G polymorphism in the μ-opioid receptor gene was believed to play an important role in this carcinogenic process. The aim of the present study was to investigate the association between the A118G polymorphism and the risk of esophageal squamous cell carcinoma (ESCC) in a Chinese population.

Method

The case–control study included 260 cancer patients and 291 controls from a Chinese Han and Chinese TuJia population in Enshi region, China. Genotypes were determined by TaqMan platform. Odds ratios (ORs) and 95 % confidence intervals (CIs) were calculated using multivariate unconditional logistic regression.

Results

Compared with the G/G genotype, the A/A genotype exhibited a significantly elevated risk for ESCC (OR = 3.12, 95 % CI [1], 1.11–6.01). A significant interaction between the A118G polymorphism and age, smoking status, and family history of cancer was also found (OR = 2.25, 95 % CI 1.36–4.12; OR = 1.75, 95 % CI 1.23–2.32; OR = 3.14, 95 % CI 1.31–7.28, respectively).

Conclusion

The A118G polymorphism in the μ-opioid receptor gene might be associated with the risk of ESCC in Chinese population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Singleton PA et al (2006) Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation. Microvasc Res 72(1–2):3–11

    Article  PubMed  CAS  Google Scholar 

  2. Parkin DM et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108

    Article  PubMed  Google Scholar 

  3. Enzinger PC, Mayer RJ (2003) Esophageal cancer. N Engl J Med 349(23):2241–2252

    Article  PubMed  CAS  Google Scholar 

  4. Bovill JG (2010) Surgery for cancer: does anesthesia matter? Anesth Analg 110(6):1524–1526

    Article  PubMed  Google Scholar 

  5. Lennon FE, Moss J, Singleton PA (2012) The mu-opioid receptor in cancer progression: is there a direct effect? Anesthesiology 116(4):940–945

    Article  PubMed  Google Scholar 

  6. Afsharimani B, Cabot P, Parat MO (2011) Morphine and tumor growth and metastasis. Cancer Metastasis Rev 30(2):225–238

    Article  PubMed  CAS  Google Scholar 

  7. Leo S, Nuydens R, Meert TF (2009) Opioid-induced proliferation of vascular endothelial cells. J Pain Res 2:59–66

    PubMed  CAS  Google Scholar 

  8. Gupta K et al (2002) Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res 62(15):4491–4498

    PubMed  CAS  Google Scholar 

  9. Su JL et al (2007) The role of the VEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer 96(4):541–545

    Article  PubMed  CAS  Google Scholar 

  10. Schultze A et al (2012) VEGFR-1 expression levels predict occurrence of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma. Clin Exp Metastasis. doi: 10.1007/s10585-012-9477-1

  11. Shabalina SA et al (2009) Expansion of the human mu-opioid receptor gene architecture: novel functional variants. Hum Mol Genet 18(6):1037–1051

    Article  PubMed  CAS  Google Scholar 

  12. Zhang Y et al (2005) Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem 280(38):32618–32624

    Article  PubMed  CAS  Google Scholar 

  13. Bortsov AV et al (2012) Mu-opioid receptor gene A118G polymorphism predicts survival in patients with breast cancer. Anesthesiology 116(4):896–902

    Article  PubMed  CAS  Google Scholar 

  14. Chou WY et al (2006) Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol Scand 50(7):787–792

    Article  PubMed  CAS  Google Scholar 

  15. Reyes-Gibby CC et al (2007) Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 130(1–2):25–30

    Article  PubMed  CAS  Google Scholar 

  16. Kamangar F et al (2009) Environmental causes of esophageal cancer. Gastroenterol Clin North Am 38(1):27–57 (vii)

    Google Scholar 

  17. Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16(3):1215

    Article  PubMed  CAS  Google Scholar 

  18. Kasai S, Ikeda K (2011) Pharmacogenomics of the human micro-opioid receptor. Pharmacogenomics 12(9):1305–1320

    Article  PubMed  CAS  Google Scholar 

  19. Tavare AN et al (2012) Cancer recurrence after surgery: direct and indirect effects of anesthetic agents. Int J Cancer 130(6):1237–1250

    Article  PubMed  CAS  Google Scholar 

  20. Gach K et al (2011) The role of morphine in regulation of cancer cell growth. Naunyn Schmiedebergs Arch Pharmacol 384(3):221–230

    Article  PubMed  CAS  Google Scholar 

  21. Biki B et al (2008) Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. Anesthesiology 109(2):180–187

    Article  PubMed  Google Scholar 

  22. Exadaktylos AK et al (2006) Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology 105(4):660–664

    Article  PubMed  Google Scholar 

  23. Ray R et al (2011) Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. Proc Natl Acad Sci USA 108(22):9268–9273

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by University Hospital of Hubei University for Nationalities and Central Hospital of Enshi Prefecture.

Conflict of interest

No author has any conflict of interest.

Author information

Authors and Affiliations

  1. Department of Anesthesiology, University Hospital of Hubei University for Nationalities, Hubei, 445000, China

    Song Wang, Yang Li, Xiang-Dong Liu & Kun-Qing Yang

  2. Department of Anesthesiology, the Central Hospital of Enshi Prefecture, Hubei, 445000, China

    Chun-Xiong Zhao

Authors
  1. Song Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yang Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiang-Dong Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chun-Xiong Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kun-Qing Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kun-Qing Yang.

About this article

Cite this article

Wang, S., Li, Y., Liu, XD. et al. Polymorphism of A118G in μ-opioid receptor gene is associated with risk of esophageal squamous cell carcinoma in a Chinese population. Int J Clin Oncol 18, 666–669 (2013). https://doi.org/10.1007/s10147-012-0441-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-012-0441-5

Keywords

Search

Navigation